-
Document de presse | 2020.04.16
Bill & Melinda Gates Medical Research Institute and the Institut Pasteur to Develop a Novel Vaccine Against Shigella
The Bill & Melinda Gates Medical Research Institute (Gates MRI) and the Institut Pasteur have entered into an exclusive collaboration and license agreement to jointly develop a quadrivalent synthetic carbohydrate-based conjugate vaccine against Shigella flexneri serotypes 2a, 3a, and 6 and Shigella sonnei. Gates MRI will have an exclusive license for manufacture and commercialization of...
-
Document de presse | 2021.10.26
The intranasal lentiviral vaccine candidate (Lenti-S) protects brain and lung in a pre-clinical animal model
The SARS-CoV-2 virus, responsible for the COVID-19 pandemic, primarily targets the respiratory tract, but its ability to infect cells of the nervous system has also been largely reported. Indeed, the expression of the receptor of this virus, the Angiotensin Converting Enzyme 2 (ACE2), by neuronal and glial cells makes the brain susceptible to SARS-CoV-2. Moreover, neurological manifestations are...
-
Document de presse | 2021.11.26
ComCor study: new results on places of infection with SARS-CoV-2 and analysis of the efficacy of messenger RNA vaccines against the Delta variant
From May 23 to August 13, 2021, the Institut Pasteur, in partnership with the French National Health Insurance Fund (CNAM), Santé publique France and the Ipsos institute, conducted the fourth part of the ComCor epidemiological study on circumstances and places of infection with the SARS-CoV-2 virus in France. The aim of the study was to identify the socio-demographic factors, places visited and...
-
Document de presse | 2022.12.19
Modelling has evaluated the role of antiviral treatment and vaccination in exiting the Zero-COVID strategy in Wallis and Futuna
By June 2022, the Wallis and Futuna Islands, a French overseas territory, had successfully implemented a Zero-COVID strategy that significantly reduced the number of SARS-CoV-2 infections. From mid-June 2022, a gradual reopening of the borders was planned. However, the relatively low immunity in the population (due to limited vaccination coverage and the number of previous infections) and the...
-
Fiche maladie | 2015.10.06
MERS-CoV
A new respiratory virus emerged in Saudi Arabia in 2012. It was named MERS-CoV, or Middle East Respiratory Syndrome Coronavirus, and it affects the respiratory tract, causing fever and a cough and proving fatal in 30% of cases. The virus has since been reported in several countries throughout the Middle East. In all, 1,219 cases have been diagnosed, leading to 449 deaths. Several cases have been...
-
Fiche maladie | 2020.01.21
COVID-19 (SARS-CoV-2 virus)
The SARS-CoV-2 coronavirus, discovered in December 2019 in the province of Wuhan in China, is responsible for COVID-19. This highly contagious emerging infectious disease spreads by airborne transmission and surface contamination. Although COVID-19 can be asymptomatic, it can also cause a variety of symptoms, including severe respiratory distress that may prove fatal. Vaccination and basic health...
-
Fiche maladie | 2015.10.06
Ebola
Ebola virus disease causes high fever and bleeding that can often prove fatal for humans. The average case fatality rate is around 50%. The Ebola virus was first discovered in 1976 following two outbreaks, one in Sudan and one in the Democratic Republic of the Congo (formerly Zaire). It was named after the Ebola river, located near the latter outbreak. Since then, several outbreaks have occurred...
-
Fiche maladie | 2019.10.02
Influenza
Influenza is a contagious respiratory infection caused by influenza viruses, which are unique due to their vast genetic variability. It is a public health issue because of the seasonal outbreaks that affect 2 to 6 million people in France every winter, with influenza-associated excess mortality estimated at approximately 10,000 deaths, mainly in vulnerable individuals. The pandemic risk...
-
News | 2024.12.16
Microbiota tailored skin humoral immunity and its potential for the development of novel vaccinal approaches
Scientists have just made two major discoveries about a harmless bacterium, Staphylococcus epidermidis, present on our skin. A first study identifies the skin as a compartment able to develop highly protective antibody responses to skin colonizing microbe in the absence of inflammation or lymph node contribution. A second study concerns the development of a topical vaccine that can be applied...
-
News | 2025.07.25
Neutralizing human monoclonal antibodies against hepatitis E virus
The Humoral Immunology Unit has identified neutralizing antibodies that are effective against the hepatitis E virus (HEV). They could be used for prevention or treatment against HEV infection, which affects approximately 20 million people worldwide every year. Structural analyses carried out with the NanoImaging Core Facility enabled atomic-scale visualization of the neutralization site...